Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
5.96
-0.25 (-4.03%)
At close: May 22, 2026, 4:00 PM EDT
6.00
+0.04 (0.67%)
After-hours: May 22, 2026, 5:31 PM EDT
Journey Medical Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Journey Medical stock has a consensus rating of "Strong Buy" and an average price target of $13.5. The average 1-year stock price forecast is 126.51% higher than the current stock price, while the lowest is $12 (+101.34%) and the highest is $16 (+168.46%).
Price Target: $13.5 (+126.51%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 26, 2026.
Analyst Ratings
The average analyst rating for Journey Medical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +118.12% | Mar 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +118.12% | Aug 25, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $9 → $13 | Strong Buy | Maintains | $9 → $13 | +118.12% | Aug 13, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +101.34% | Jul 30, 2025 |
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +51.01% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
84.28M
from 61.86M
Increased by 36.24%
Revenue Next Year
140.49M
from 84.28M
Increased by 66.70%
EPS This Year
0.07
from -0.47
EPS Next Year
1.06
from 0.07
Increased by 1,331.03%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 90.7M | 165.8M | |
| Avg | 84.3M | 140.5M | |
| Low | 77.1M | 117.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 46.6% | 96.7% | |
| Avg | 36.2% | 66.7% | |
| Low | 24.6% | 39.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.23 | 1.85 | |
| Avg | 0.07 | 1.06 | |
| Low | -0.05 | 0.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 2,399.0% | |
| Avg | - | 1,331.0% | |
| Low | - | 496.3% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.